Ponatinib Hydrochloride

DRUG8 trials

Sponsors

M.D. Anderson Cancer Center, OHSU Knight Cancer Institute, Mayo Clinic, Sameek Roychowdhury, National Cancer Institute (NCI)

Conditions

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAdult Acute Lymphoblastic Leukemia in Complete RemissionB Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveChronic Myelomonocytic Leukemia

Phase 1

Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia

CompletedNCT02779283

OHSU Knight Cancer InstituteAcute Lymphoblastic Leukemia, Acute Myeloid Leukemia

Start: 2016-01-13End: 2018-09-20Updated: 2020-05-26

Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia

TerminatedNCT03576547

M.D. Anderson Cancer CenterBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, Recurrent Acute Lymphoblastic Leukemia +4

Start: 2018-06-26End: 2024-06-19Updated: 2025-05-08

Phase 2

Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia

Active, not recruitingNCT01424982

M.D. Anderson Cancer CenterAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Adult Acute Lymphoblastic Leukemia in Complete Remission +4

Start: 2011-10-05End: 2027-10-31Updated: 2025-12-05

Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

TerminatedNCT01620216

OHSU Knight Cancer InstituteAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Recurrent Acute Lymphoblastic Leukemia +3

Start: 2012-05-11End: 2017-04-30Updated: 2021-11-04

Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib

RecruitingNCT01746836

M.D. Anderson Cancer CenterChronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Start: 2013-01-17End: 2030-12-31Target: 50Updated: 2026-03-09

Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions

CompletedNCT02265341

Mayo ClinicMalignant Hepatobiliary Neoplasm

Start: 2014-12-31End: 2019-06-14Updated: 2020-11-25

Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.

CompletedNCT02272998

Sameek RoychowdhuryMalignant Neoplasm

Start: 2015-02-24End: 2022-11-17Updated: 2025-03-24

Phase 3

Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

Active, not recruitingNCT04530565

National Cancer Institute (NCI)B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1

Start: 2021-01-25End: 2028-07-01Target: 348Updated: 2026-04-03

Related Papers

P-1934. Incidence of Neurotoxicity Among Patients with Leukemia Receiving Vincristine and Azole Prophylaxis

Open Forum Infectious Diseases2026-01-01

Ponatinib vs. Imatinib as Frontline Treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Matching Adjusted Indirect Comparison.

2023-05-1913 citations

Frontline combination of ponatinib and <scp>hyper‐CVAD</scp> in Philadelphia chromosome‐positive acute lymphoblastic leukemia: 80‐months follow‐up results

American Journal of Hematology2023-01-0484 citations

Prognostic Significance of Genetic Alterations in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Hyper-CVAD Plus Dasatinib or Hyper-CVAD Plus Ponatinib

Blood2020-11-042 citations

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study.

2018-12-01185 citations

A pilot study of ponatinib in cholangiocarcinoma patients with FGFR2 fusions.

Journal of Clinical Oncology2018-02-013 citations

Frontline hyper-CVAD plus ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Updated results of a phase II study.

Journal of Clinical Oncology2017-05-2022 citations

A Phase II Pilot Study of Kinase Inhibition in Relapsed/Refractory Acute Leukemias: Using an in Vitro Kinase Inhibitor Panel to Select Individualized, Targeted Therapies

Blood2016-12-02

Updated results from phase II study of combination of hyper-CVAD (HCVAD) with ponatinib in frontline therapy of patients (pts) with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).

Journal of Clinical Oncology2016-05-205 citations

Propensity score analysis: Frontline therapy with hyper-CVAD (HCVAD) + ponatinib vs. HCVAD + dasatinib in patients (pts) with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).

Journal of Clinical Oncology2016-05-201 citations

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study.

2015-09-30204 citations

Abstract 783: Ponatinib demonstrates antitumor activity in RET- and FGFR-driven patient-derived xenografts

Cancer Research2015-08-01

Phase II study of combination of hyperCVAD with ponatinib in frontline therapy of patients (pts) with Philadelphia chromosome (Ph) positive acute lymphoblastic leukemia (ALL).

Journal of Clinical Oncology2014-05-204 citations